Cancer Biological Therapy Market Research Report by Product, Distribution Channel, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030- Product Image

Sale

Cancer Biological Therapy Market Research Report by Product, Distribution Channel, State - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - United States Forecast 2023-2030

Report
121 Pages
January 2023
Region: United States
360iResearch™
ID: 5336921

UP TO €861EUR$895USD£760GBP OFF until Mar 31^st 2023

The United States Cancer Biological Therapy Market size was estimated at USD 12.46 billion in 2022, USD 14.23 billion in 2023 and is projected to grow at a CAGR of 12.25% to reach USD 31.43 billion by 2030.

Cumulative Impact of COVID-19:

COVID-19 is an unprecedented global public health emergency that affected almost every industry, and the long-term impacts are projected to reflect on the growth of various end-use industries during the forecast period. This ongoing research amplifies the research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19, considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The dedicated section in the report uncovers a detailed analysis of the impact of COVID-19 and its subsequent variant outbreaks on demand, supply, price, and vendor uptake and provides recommendations for sustainable outcomes. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the United States Cancer Biological Therapy Market.

Cumulative Impact of Russia-Ukraine Conflict:

The publisher continuously monitors and update reports considering unceasing political and economic uncertainty due to the Russia-Ukraine Conflict. Negative impacts are globally foreseen, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected people’s lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on Ukraine and reverberate harsh long-term effects on Russia. The report uncovers the implications for demand-supply balances, pressure on pricing variants, impact on import/export and trading, and short-term recommendations to the United States Cancer Biological Therapy Market considering the current update on the conflict and its global responses.

Cumulative Impact of High Inflation:

The high inflation in developed economies globally has resulted in an overall price surge over the past two years. The cumulatively eroding overall purchasing power is expected to impact developing economies significantly and is considered helpful in numerous ways. The report uncovers the effect of high inflation on the long-term performance of the global economy and provides details on fiscal policies measuring and reducing its short-term impacts on demand/supply, cash flow, and currency exchange. The United States Cancer Biological Therapy Market report delivers the high inflation expectation considering the related impact from cost-push and demand-pull inflation.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make better decisions. In this report, the years 2018 and 2021 are considered as historical years, 2022 as the base year, 2023 as the estimated year, and years from 2024 to 2030 are considered as the forecast period.

Market Segmentation & Coverage:

The report on the United States Cancer Biological Therapy Market identifies key attributes about the customer to define the potential market and identify different needs across the industry. Understanding the potential customer group's economies and geographies can help gain business acumen for better strategic decision-making. The market coverage across different industry verticals reveals the hidden truth about the players' strategies in different verticals and helps the organization decide target audience. This report gives you the composite view of sub-markets coupled with comprehensive industry coverage and provides you with the right way of accounting factors such as norms & regulations, culture, to make right coverage strategy for your market plan. This research report categorizes the United States Cancer Biological Therapy Market in order to forecast the revenues and analyze the trends in each of the following sub-markets:

Based on Product, the market is studied across Cancer Growth Blockers, Monoclonal Antibodies, and Vaccines.
Based on Distribution Channel, the market is studied across Hospital and Retail & Mail Order Pharmacies.
Based on State, the market is studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas.

FPNV Positioning Matrix:

The FPNV Positioning Matrix evaluates and categorizes vendors in the United States Cancer Biological Therapy Market. based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) and placed into four quadrants (F: Forefront, P: Pathfinder, N: Niche, and V: Vital). The United States Cancer Biological Therapy Market FPNV Positioning Matrix representation/visualization further aids businesses in better decision-making and understanding the competitive landscape.

Market Share Analysis:

The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market, providing the idea of revenue generation into the overall market compared to other vendors in the space. This provides insights on vendors performance in terms of revenue generation and customer base compared to others. The United States Cancer Biological Therapy Market Share Analysis offers an idea of the size and competitiveness of the vendors for the base year. The outcome reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.

Competitive Scenario:

The Competitive Scenario provides an outlook analysis of the various strategies for business growth adopted by the vendors. The news in this section covers valuable insights at various stages while keeping up with the business and engaging stakeholders in the economic debate. The United States Cancer Biological Therapy Market Competitive Scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected helps vendors understand the gaps in the marketplace and competitor’s strengths and weaknesses, providing insights to enhance products and services.

Company Usability Profiles:

The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the United States Cancer Biological Therapy Market, including AbbVie, Inc, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol-Myers Squibb, Eisai Co., Ltd., Eli Lilly and Company, F. Hoffmann-La Roche AG, GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Incyte Corp, Johnson & Johnson Services, Inc,, Merck & Co., Inc., Novartis International AG, Otsuka Pharmaceutical Co., Ltd, Sanofi SA, Spectrum Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, and Teva Pharmaceutical Industries Ltd.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation
5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the United States Cancer Biological Therapy Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the United States Cancer Biological Therapy Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the United States Cancer Biological Therapy Market?
4. What is the competitive strategic window for opportunities in the United States Cancer Biological Therapy Market?
5. What are the technology trends and regulatory frameworks in the United States Cancer Biological Therapy Market?
6. What is the market share of the leading vendors in the United States Cancer Biological Therapy Market?
7. What modes and strategic moves are considered suitable for entering the United States Cancer Biological Therapy Market?

Frequently Asked Questions about the U.S. Cancer Biological Therapy Market

What is the estimated value of the U.S. Cancer Biological Therapy Market?

The U.S. Cancer Biological Therapy Market was estimated to be valued at $12.46 Billion in 2022.

What is the growth rate of the U.S. Cancer Biological Therapy Market?

The growth rate of the U.S. Cancer Biological Therapy Market is 12.2%, with an estimated value of $31.43 Billion by 2030.

What is the forecasted size of the U.S. Cancer Biological Therapy Market?

The U.S. Cancer Biological Therapy Market is estimated to be worth $31.43 Billion by 2030.

Who are the key companies in the U.S. Cancer Biological Therapy Market?

Key companies in the U.S. Cancer Biological Therapy Market include AbbVie, Inc, Astellas Pharma Inc., AstraZeneca PLC, Bausch Health Companies Inc., Bayer AG, Bristol, Myers Squibb, Eisai Co., Ltd. and F. Hoffmann.

Report Attribute	Details
No. of Pages	121
Published	January 2023
Forecast Period	2022 - 2030
Estimated Market Value ( USD ) in 2022	$ 12.46 Billion
Forecasted Market Value ( USD ) by 2030	$ 31.43 Billion
Compound Annual Growth Rate	12.2%
Regions Covered	United States
No. of Companies Mentioned	20

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing elderly population and risk of cancer globally
5.1.1.2. Growing awareness about cancer biological therapy
5.1.2. Restraints
5.1.2.1. High cost of cancer biological therapy
5.1.3. Opportunities
5.1.3.1. Technological advancements in cancer biologics therapy
5.1.4. Challenges
5.1.4.1. Side-effects associated with cancer cancer biological therapy
5.2. Cumulative Impact of COVID-19
5.3. Cumulative Impact of Russia-Ukraine Conflict
5.4. Cumulative Impact of High Inflation
5.5. Porter’s Five Forces Analysis
5.5.1. Threat of New Entrants
5.5.2. Threat of Substitutes
5.5.3. Threat of Substitutes
5.5.4. Threat of Substitutes
5.5.5. Industry Rivalry
5.6. Value Chain & Critical Path Analysis
5.7. Regulatory Framework
5.8. Client Customization

6. Cancer Biological Therapy Market, by Product
6.1. Introduction
6.2. Cancer Growth Blockers
6.3. Monoclonal Antibodies
6.4. Vaccines

7. Cancer Biological Therapy Market, by Distribution Channel
7.1. Introduction
7.2. Hospital
7.3. Retail & Mail Order Pharmacies

8. California Cancer Biological Therapy Market
8.1. Introduction

9. Florida Cancer Biological Therapy Market
9.1. Introduction

10. Illinois Cancer Biological Therapy Market
10.1. Introduction

11. New York Cancer Biological Therapy Market
11.1. Introduction

12. Ohio Cancer Biological Therapy Market
12.1. Introduction

13. Pennsylvania Cancer Biological Therapy Market
13.1. Introduction

14. Texas Cancer Biological Therapy Market
14.1. Introduction

15. Competitive Landscape
15.1. FPNV Positioning Matrix
15.1.1. Quadrants
15.1.2. Business Strategy
15.1.3. Product Satisfaction
15.2. Market Ranking Analysis, By Key Player
15.3. Market Share Analysis, By Key Player
15.4. Product Portfolio Analysis, By Key Player
15.5. Competitive Scenario
15.5.1. Merger & Acquisition
15.5.2. Agreement, Collaboration, & Partnership
15.5.3. New Product Launch & Enhancement
15.5.4. Investment & Funding
15.5.5. Award, Recognition, & Expansion

16. Company Usability Profiles
16.1. AbbVie, Inc
16.2. Astellas Pharma Inc.
16.3. AstraZeneca PLC
16.4. Bausch Health Companies Inc.
16.5. Bayer AG
16.6. Bristol-Myers Squibb
16.7. Eisai Co., Ltd.
16.8. Eli Lilly and Company
16.9. F. Hoffmann-La Roche AG
16.10. GlaxoSmithKline PLC
16.11. Hikma Pharmaceuticals PLC
16.12. Incyte Corp
16.13. Johnson & Johnson Services, Inc,
16.14. Merck & Co., Inc.
16.15. Novartis International AG
16.16. Otsuka Pharmaceutical Co., Ltd
16.17. Sanofi SA
16.18. Spectrum Pharmaceuticals, Inc.
16.19. Takeda Pharmaceutical Company Limited
16.20. Teva Pharmaceutical Industries Ltd

17. Appendix
17.1. Discussion Guide
17.2. License & Pricing

List of Figures
FIGURE 1. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: RESEARCH PROCESS
FIGURE 2. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2022 VS 2030
FIGURE 3. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 4. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 5. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 6. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY STATE, 2030
FIGURE 7. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET DYNAMICS
FIGURE 8. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET PORTER’S FIVE FORCES ANALYSIS
FIGURE 9. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
FIGURE 10. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 11. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY PRODUCT, 2030
FIGURE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, 2018-2030 (USD BILLION)
FIGURE 13. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
FIGURE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
FIGURE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2030 (%)
FIGURE 16. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2022 VS 2023 VS 2030 (USD BILLION)
FIGURE 17. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET COMPETITIVE STRATEGIC WINDOW, BY DISTRIBUTION CHANNEL, 2030
FIGURE 18. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, 2018-2030 (USD BILLION)
FIGURE 19. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, 2018-2030 (USD BILLION)
FIGURE 20. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 21. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 22. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 23. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 24. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 25. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 26. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
FIGURE 27. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX, 2022
FIGURE 28. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2022
FIGURE 29. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET COMPETITIVE SCENARIO, BY KEY TYPE, 2022List of Tables
TABLE 1. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 4. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD BILLION)
TABLE 5. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 6. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, 2018-2030 (USD BILLION)
TABLE 7. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY CANCER GROWTH BLOCKERS, BY STATE, 2018-2030 (USD BILLION)
TABLE 8. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, 2018-2030 (USD BILLION)
TABLE 9. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY STATE, 2018-2030 (USD BILLION)
TABLE 10. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, 2018-2030 (USD BILLION)
TABLE 11. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY VACCINES, BY STATE, 2018-2030 (USD BILLION)
TABLE 12. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 13. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, 2018-2030 (USD BILLION)
TABLE 14. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY HOSPITAL, BY STATE, 2018-2030 (USD BILLION)
TABLE 15. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, 2018-2030 (USD BILLION)
TABLE 16. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SIZE, BY RETAIL & MAIL ORDER PHARMACIES, BY STATE, 2018-2030 (USD BILLION)
TABLE 17. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 18. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 19. CALIFORNIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 20. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 21. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 22. FLORIDA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 23. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 24. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 25. ILLINOIS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 26. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 27. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 28. NEW YORK CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 29. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 30. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 31. OHIO CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 32. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 33. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 34. PENNSYLVANIA CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 35. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, 2018-2030 (USD BILLION)
TABLE 36. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD BILLION)
TABLE 37. TEXAS CANCER BIOLOGICAL THERAPY MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD BILLION)
TABLE 38. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - SCORES, 2022
TABLE 39. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - BUSINESS STRATEGY, 2022
TABLE 40. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: FPNV POSITIONING MATRIX - PRODUCT SATISFACTION, 2022
TABLE 41. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET RANKING, BY KEY PLAYER, 2022
TABLE 42. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET SHARE, BY KEY PLAYER, 2022
TABLE 43. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET PRODUCT PORTFOLIO ANALYSIS, BY KEY PLAYER, 2022
TABLE 44. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET MERGER & ACQUISITION
TABLE 45. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET AGREEMENT, COLLABORATION, & PARTNERSHIP
TABLE 46. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET NEW PRODUCT LAUNCH & ENHANCEMENT
TABLE 47. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET INVESTMENT & FUNDING
TABLE 48. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET AWARD, RECOGNITION, & EXPANSION
TABLE 49. UNITED STATES CANCER BIOLOGICAL THERAPY MARKET: LICENSE & PRICING